Literature DB >> 7516157

Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease.

P N Hawkins1, M N Rossor, J R Gallimore, B Miller, E G Moore, M B Pepys.   

Abstract

Serum amyloid P component (SAP) is a normal plasma protein produced in the liver and co-deposited with amyloid fibrils in all types of amyloidosis, including cerebral beta-protein amyloid deposits associated with Alzheimer's disease (AD). We have measured its concentration and those of alpha 2-macroglobulin, IgG and albumin in the CSF of 51 patients with AD and 50 healthy and disease control subjects. The mean levels of SAP were 12.8 ng/ml in AD and 8.5 ng/ml in controls (P < 0.0125); there was no difference in the levels of the other proteins studied. The observed concentrations of SAP were much lower than expected for a protein of molecular weight 254620. The difference between AD and controls suggests that the concentration of SAP in the CSF may be affected by the presence of cerebral amyloidosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516157     DOI: 10.1006/bbrc.1994.1760

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Inhibition of fibrocyte differentiation by serum amyloid P.

Authors:  Darrell Pilling; Christopher D Buckley; Mike Salmon; Richard H Gomer
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

Review 2.  In vivo amyloid imaging in Alzheimer's disease.

Authors:  H I Sair; P M Doraiswamy; J R Petrella
Journal:  Neuroradiology       Date:  2004-01-23       Impact factor: 2.804

3.  Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation.

Authors:  Diane D Shao; Rahul Suresh; Varsha Vakil; Richard H Gomer; Darrell Pilling
Journal:  J Leukoc Biol       Date:  2008-03-10       Impact factor: 4.962

4.  Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.

Authors:  Simon E Kolstoe; Basil H Ridha; Vittorio Bellotti; Nan Wang; Carol V Robinson; Sebastian J Crutch; Geoffrey Keir; Riitta Kukkastenvehmas; J Ruth Gallimore; Winston L Hutchinson; Philip N Hawkins; Stephen P Wood; Martin N Rossor; Mark B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

5.  Efflux transport of serum amyloid P component at the blood-brain barrier.

Authors:  Szilvia Veszelka; Judit Laszy; Tamás Pázmány; László Németh; Izabella Obál; László Fábián; Gábor Szabó; Csongor S Abrahám; Mária A Deli; Zoltán Urbányi
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2013-11-21

6.  Alcohol consumption, interleukin-6 and apolipoprotein E genotypes, and concentrations of interleukin-6 and serum amyloid P in older adults.

Authors:  Kenneth J Mukamal; Nancy S Jenny; Russell P Tracy; David S Siscovick
Journal:  Am J Clin Nutr       Date:  2007-08       Impact factor: 7.045

7.  Dementia in the older population is associated with neocortex content of serum amyloid P component.

Authors:  Stephan Ellmerich; Graham W Taylor; Connor D Richardson; Thais Minett; Amand Floriaan Schmidt; Carol Brayne; Fiona E Matthews; Paul G Ince; Stephen B Wharton; Mark B Pepys
Journal:  Brain Commun       Date:  2021-10-09

8.  Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.

Authors:  Kumiko Shirai; Hayato Hikita; Sadatsugu Sakane; Ryohei Narumi; Jun Adachi; Akira Doi; Satoshi Tanaka; Yuki Tahata; Ryoko Yamada; Takahiro Kodama; Ryotaro Sakamori; Tomohide Tatsumi; Eiji Mita; Takeshi Tomonaga; Tetsuo Takehara
Journal:  PLoS One       Date:  2022-07-07       Impact factor: 3.752

9.  Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo.

Authors:  Raya Al-Shawi; Glenys A Tennent; David J Millar; Angela Richard-Londt; Sebastian Brandner; David J Werring; J Paul Simons; Mark B Pepys
Journal:  Open Biol       Date:  2016-02       Impact factor: 6.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.